Sugi Predict

Sugi Predict / Compounds / SCHEMBL3049060

SCHEMBL3049060

SCHEMBL3049060

CC(C)(CNC(=O)OC(C)(C)C)CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ TDP1 Q9NUW8 2/20 0.49
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ CPT2 P23786 1/20 0.41
▸ CA1 P00915 3/20 0.41
▸ CA2 P00918 3/20 0.41
▸ CA12 O43570 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CTSS P25774 2/20 0.37
▸ CTSK P43235 2/20 0.37
▸ EPHX1 P07099 1/20 0.37
▸ KDM4A O75164 1/20 0.37
▸ HMGCR P04035 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ TBXA2R P21731 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24746515 0.91 MEN1 (0.46) MEN1GAAKMT2ATDP1MAOA
SCHEMBL23418149 0.88 MEN1 (0.44) MEN1GAAKMT2ATDP1MAOA
SCHEMBL21065336 0.86 TDP1 (0.52) MEN1GAAKMT2ATDP1MAOA
SCHEMBL628982 0.84 TDP1 (0.43) MEN1GAAKMT2ATDP1KDM4E
SCHEMBL20415322 0.83 MEN1 (0.43) MEN1GAAKMT2ATDP1MAOA
SCHEMBL1536313 0.83 HMGCR (0.50) MEN1GAAKMT2ATDP1MAOA
SCHEMBL2374951 0.83 HMGCR (0.50) MEN1GAAKMT2ATDP1MAOA
SCHEMBL7757574 0.83 TDP1 (0.43) MEN1GAAKMT2ATDP1MAOA
SCHEMBL24899376 0.81 MEN1 (0.56) MEN1GAAKMT2ATDP1MAOA
SCHEMBL5548918 0.81 MEN1 (0.47) MEN1GAAKMT2ATDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055373-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 — — CN disclosed
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-04-02 — — US disclosed
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-02-12 — — US disclosed
US-12472165-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-11-18 — — US disclosed
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN THERAPEUTICS LTD (US) 2025-10-30 — — US disclosed
EP-4566608-A2 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION Gilead Sciences, Inc. (US) 2025-06-11 — — EP disclosed
US-20250179102-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2025-06-05 — — US disclosed
EP-4440702-B1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES INC (US) 2025-05-21 — — EP disclosed
EP-4445900-B1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES INC (US) 2025-05-21 — — EP disclosed
US-12295942-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-05-13 — — US disclosed
WO-2014067960-A9 FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-07-09 — — WO disclosed
WO-2014067960-A9 FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-07-09 — — WO disclosed
WO-2014067960-A2 FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-05-08 — — WO disclosed
WO-2014067960-A2 FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-05-08 — — WO disclosed
EP-1713822-B1 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2010-03-17 — — EP disclosed
US-20100003216-A1 HCV NS-3 Serine Protease Inhibitors MEDIVIR AB (SE) 2010-01-07 — — US disclosed
US-7608590-B2 HCV NS-3 serine protease inhibitors MEDIVIR AB (SE) 2009-10-27 — — US disclosed
US-20070161574-A1 Hcv ns-3 serine protease inhibitors MEDIVIR AB (SE) 2007-07-12 — — US disclosed
EP-1713822-A2 HCV NS-3 SERINE PROTEASE INHIBITORS Medivir Aktiebolag (SE) 2006-10-25 — — EP disclosed
WO-2005073216-A2 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2005-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003216-A1 HCV NS-3 Serine Protease Inhibitors SPINT2, SF3A3, GTF3C3 MEN1 4570/4885GAA 2981/4885KMT2A 4582/4885
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE IL6ST, GFRA3, GFRA1 MEN1 3255/4885GAA 2244/4885KMT2A 3288/4885
US-20070161574-A1 Hcv ns-3 serine protease inhibitors PRSS1, HPN, SPINT2 MEN1 4639/4885GAA 3103/4885KMT2A 4573/4885
US-20250179102-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION CD4, HAVCR2, MAVS MEN1 4379/4885GAA 225/4885KMT2A 3605/4885
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE GFRA3, IL6ST, GFRA1 MEN1 3290/4885GAA 2222/4885KMT2A 3363/4885
US-12472165-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 MEN1 1667/4885GAA 510/4885KMT2A 2213/4885
US-12295942-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 MEN1 1667/4885GAA 510/4885KMT2A 2213/4885
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 MEN1 1667/4885GAA 510/4885KMT2A 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.